言語を選択

Siglec-3

Siglec-3 詳細

英語名	Myeloid cell surface antigen CD33	市販薬剤の数	1
治験薬の数	44	ターゲットの別称	Myeloid Cell Surface Antigen CD33，CD33 Molecule Transcript，CD33 Antigen，Siglec-3，P67，FLJ00391，Sialic acid-binding Ig-like lectin 3，CD33，CD33 Molecule，CD33 Antigen (Gp67)，SIGLEC3，Gp67，Sialic Acid Binding Ig-Like Lectin 3
研究＆開発段階	Approved

英語名	Myeloid cell surface antigen CD33
ターゲットの別称	Myeloid Cell Surface Antigen CD33，CD33 Molecule Transcript，CD33 Antigen，Siglec-3，P67，FLJ00391，Sialic acid-binding Ig-like lectin 3，CD33，CD33 Molecule，CD33 Antigen (Gp67)，SIGLEC3，Gp67，Sialic Acid Binding Ig-Like Lectin 3
市販薬剤の数	1
治験薬の数	44
研究＆開発段階	Approved

Siglec-3 製品リスト

属性
Protein (17)Beads (1)
製品ライブラリ
オンライン (18)
種
Human (15)Cynomolgus (1)Mouse (1)Rat (1)
タグ
His Tag (9)Fc Tag (4)His Tag & Avi Tag (2)- (1)Fc Tag & Avi Tag (1)Llama IgG Fc Tag (1)
マーカー
Unconjugated (8)Biotin-labeled (3)FITC Labeled (2)- (1)PE Labeled (2)AF647 Labeled (1)APC Labeled (1)

製品番号	種	発現システム	製品説明
HOT CD3-H5226	Human	HEK293	Human Siglec-3 / CD33 Protein, His Tag (MALS verified)
HOT CD3-H82E7	Human	HEK293	Biotinylated Human Siglec-3 / CD33 Protein, Avitag™,His Tag (MALS verified)
HOT CD3-HP2E3	Human	HEK293	PE-Labeled Human Siglec-3 / CD33 Protein, His Tag (Site-specific conjugation)
HOT CD3-C52H4	Cynomolgus	HEK293	Cynomolgus Siglec-3 / CD33 Protein, His Tag (MALS verified)
CD3-H5254	Human	HEK293	Human Siglec-3 / CD33 (R119G) Protein, Fc Tag
CD3-H5255	Human	HEK293	Human Siglec-3 / CD33 (18-132) Protein, Fc Tag
CD3-H5257	Human	HEK293	Human Siglec-3 / CD33 Protein, Fc Tag (MALS verified)
CD3-H5258	Human	HEK293	Human Siglec-3 / CD33 (140-232) Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
CD3-H82E9	Human	HEK293	Biotinylated Human Siglec-3 / CD33 (G69R) Protein, Avitag™,His Tag (MALS verified)
CD3-H82F3	Human	HEK293	Biotinylated Human Siglec-3 / CD33 Protein, Fc,Avitag™ (MALS verified)

総数量18

Siglec-3バックグランド

Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Iglike lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V-type domain, one Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.

Siglec-3分子の別称

CD33,SIGLEC3,gp67

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
BL-M11D1	BL-M11D1	Phase 3 Clinical	Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
BI-836858	BI-836858	Phase 2 Clinical	C.H. Boehringer Sohn Ag & Co. Kg	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
CART-33 (Chinese PLA General Hospital)		Phase 2 Clinical	Pla General Hospital	Leukemia, Myeloid; Leukemia, Myeloid, Acute	詳細
Lintuzumab Ac-225	AC225-MOAB-M195; HuM195-Ac-225; 225Ac-HuM-195	Phase 2 Clinical	Pdl Biopharma Inc	Glioblastoma; Glioma; Gliosarcoma; Leukemia, Myeloid, Acute; Multiple Myeloma	詳細
CLL1/CD33/CD38/CD7 CAR-T cell therapy		Phase 2 Clinical	Guangzhou Bio-Gene Technology Co Ltd	Leukemia, Myeloid, Acute	詳細
Universal donor derived CD33 CAR-NK cell therapy (Nationwide Children'S Hospital)		Phase 2 Clinical	Nationwide Children'S Hospital	Leukemia, Myeloid, Acute	詳細
CD33-CD123-CLL1 CART-T cell therapy (Hebei Taihe Chunyu Biotechnology)		Phase 2 Clinical	Hebei Tahoe Chunyu Biotechnology Co Ltd	Leukemia, Myeloid	詳細
VBP-301	VBP301; VBP-301	Phase 2 Clinical	Vor Biopharma Inc	Leukemia, Myeloid, Acute	詳細
VBP-101	VBP101; VBP-101	Phase 2 Clinical	Vor Biopharma Inc	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech)	BAH244; BAH-244	Phase 2 Clinical	Essen Biotech	Leukemia, Myeloid, Acute	詳細
MP0533	MP0533	Phase 2 Clinical	Molecular Partners Ag	Leukemia, Myeloid, Acute	詳細
CD33 CAR T Cells(Beijing Boren Hospital)		Phase 2 Clinical	Beijing Gao Boren Hospital Co Ltd	Leukemia; Leukemia, Myeloid, Acute; Neoplasms	詳細
Emerfetamab	AMG-673; AMG673	Phase 1 Clinical	Amgen Inc	Leukemia, Myeloid, Acute	詳細
ICG-136	ICG-136; 123b-33bcCAR	Phase 1 Clinical	Icell Gene Therapeutics (Int'L) Ltd	Leukemia, Myeloid, Acute	詳細
AL-003	AL-003	Phase 1 Clinical	Abbvie Inc, Alector Inc	Alzheimer Disease	詳細
PRGN-3006	PRGN-3006; PRGN-3006 UltraCAR-T	Phase 1 Clinical	Precigen Inc	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
anti-CD33 (FL-33) CAR T-cell therapy (Beijing GoBroad Hospital)		Phase 1 Clinical	Beijing Gao Boren Hospital Co Ltd	Leukemia, Myeloid, Acute	詳細
anti-CD33/anti-CLL-1 CAR T-cell therapy (Nanjing Legend Biotech)		Phase 1 Clinical		Leukemia, Myeloid, Acute	詳細
ORM-6151	ORM-6151; BMS-986497	Phase 1 Clinical	Orum Therapeutics Inc	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
SENTI-202	SENTI-202	Phase 1 Clinical	Senti Biosciences Inc	Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
CD33Bi FPBMC (University Of Virginia)		Phase 1 Clinical	University Of Virginia	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases	詳細
A-CAR028	A-CAR028	Phase 1 Clinical	Cellular Biomedicine (Shanghai) Co Ltd	Leukemia, Myeloid, Acute	詳細
ACLX-004	ACLX-004	Phase 1 Clinical	Arcellx Inc	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
JNJ-89853413	JNJ-89853413	Phase 1 Clinical	Janssen Research & Development Llc	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
GTB-3650	GTB-3650; GTB-360; OXS-3350; OXS-C3550	Phase 1 Clinical	Masonic Cancer Center, University Of Minnesota	Bone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
RJK-RT2831	RJK-RT2831; RJKRT2831; RT-2831; RT2831	Phase 1 Clinical	Nanjing RegeneCore Biotech Co Ltd	Hematologic Neoplasms	詳細
JNJ-67571244	JNJ-1244; JNJ-67571244; JNJ-67371244	Phase 1 Clinical	Johnson & Johnson	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
CD33-NKE	CD33-NKE	Phase 1 Clinical	Bristol-Myers Squibb Company	Leukemia, Myeloid, Acute	詳細
Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital)		Phase 1 Clinical	Beijing GoBroad Hospital	Leukemia, Myeloid, Acute	詳細
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute)		Phase 1 Clinical	Shenzhen Geno-Immune Medical Institute	Leukemia, Myeloid, Acute	詳細
CD33/CLL1 dual CAR-NK cell therapy (Hangzhou Qihan)		Phase 1 Clinical	Hangzhou Qihan Biotechnology Co Ltd	Leukemia, Myeloid, Acute; Neoplasm, Residual	詳細
CD33 CAR-NK cell therapy (Hangzhou Qihan)		Phase 1 Clinical	Hangzhou Qihan Biotechnology Co Ltd	Leukemia, Myeloid, Acute; Neoplasm, Residual	詳細
Eluvixtamab	AMG-330; MT-114	Phase 1 Clinical	Amgen Inc	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
IBR-733	IBR-733; IBR733	Phase 1 Clinical	Imbioray (Hangzhou) Biomedicine Co Ltd	Leukemia, Myeloid, Acute	詳細
Anti-CD33 chimeric antigen receptor T cell therapy (Shanghai YaKe/Zhejiang University)		Phase 1 Clinical	Shanghai YaKe Biotechnology Co Ltd	Leukemia, Myeloid, Acute	詳細
CLL1+CD33 CAR-T(Zhejiang University)		Phase 1 Clinical	Zhejiang University	Leukemia, Myeloid, Acute	詳細
anti-CD33 CAR T cells therapy（iCell Gene Therapeutics）		Phase 1 Clinical	Icell Gene Therapeutics (Int'L) Ltd	Hematologic Neoplasms; Leukemia, Myeloid, Acute	詳細
Lintuzumab Ac-225/Venetoclax		Phase 1 Clinical	Actinium Pharmaceuticals Inc	Leukemia, Promyelocytic, Acute	詳細
SC-DARIC33	SC-DARIC33; DARIC-33	Phase 1 Clinical	Genetix Biotherapeutics Inc	Leukemia, Myeloid, Acute	詳細
DXC-007	DXC-007	Phase 1 Clinical	Hangzhou Dac Biotech Company Ltd	Leukemia; Leukemia, Myeloid, Acute	詳細
Lintuzumab-gelonin conjugate		Phase 1 Clinical	The University Of Texas MD Anderson Cancer Center	Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	詳細
Anti-CD33/CLL-1 CAR-T (Legend)		Phase 1 Clinical	Legend Biotech Corp	Leukemia, Promyelocytic, Acute	詳細
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)		Phase 1 Clinical	University Of California San Diego	Leukemia, Myeloid, Acute	詳細
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid)		Clinical	Wuhan BioRaid Biotechnology Co Ltd	Leukemia, Myeloid, Acute	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Gemtuzumab ozogamicin	CMA-676; CDP-771; WAY-CMA-676; CL-555201; hP67.6-calicheamicin	Approved	Pfizer Inc, Ucb Sa	Mylotarg	Japan	Leukemia, Myeloid, Acute	Pfizer Inc	2008-01-18	Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes	詳細

レビュー

K***n2023-05-06
0評価
PE-Labeled Human Siglec-3 / CD33 Protein, His TagStar Staining
While transducing primary cells, I was running into a staining issue with biotinylated-rCD33. A colleague of mine had used rCD33 labelled with PE before and had success with a similar experiment. I decided to order from Acrobio Systems due to the recommendations and high praise from several colleagues. Upon staining, I saw great fluorescence, increased events caught, and higher transduction efficiencies. I will definitely be using this product again!
E***g2023-01-18
4評価
PE-Labeled Human Siglec-3 / CD33 Protein, His Tag (Site-specific conjugation)
We purchased this reagent for use in detecting CD33 CAR expression and it worked as advertised. The PE signal gave great separation by flow cytometry and allowed for the clear detection of CAR expression on the surface of our cells. The product page states that the CD33 PE reagent is incompatible with streptavidin-biotin detection systems. When we tried to co-stain with another biotinylated reagent, subsequent application of streptavidin-APC resulted in high non-specific APC staining. This could be avoided by staining with CD33 PE after all other staining steps have been completed.
S***s2023-01-12
0評価
PE-Labeled Human Siglec-3 / CD33 Protein, His Tag (Site-specific conjugation)
We purchased this antibody to use for flow cytometry on a client study, who specifically requested Acro antibodies! They are reliable and have continued to be one of our top providers of antibodies. We typically use multiple fluorescent antibodies with various protein targets and fluorophores at once for flow cytometry panels in human and mouse tissues, and Acro antibodies have always given us a great readout.